{"title":"Optimal management for osteoporotic vertebral compression fractures: a network meta-analysis.","authors":"Yan Li, Xianghong Wang, Jianfeng Sun, Maozhen Ma","doi":"10.1186/s13018-025-06233-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Optimal management of osteoporotic vertebral compression fractures (OVCFs) remains controversial. This network meta‑analysis (NMA) evaluated the relative efficacy and safety of third‑generation percutaneous vertebral augmentation (TVA), percutaneous kyphoplasty (PKP), percutaneous vertebroplasty (PVP), and non‑surgical management (NSM) in OVCFs.</p><p><strong>Methods: </strong>A systematic search of PubMed, Embase, the Cochrane Library, and Web of Science was conducted from inception to February 1, 2025, to identify clinical trials comparing ≥ 2 of these interventions. Primary outcomes included pain intensity (Visual Analog Scale [VAS]), functional disability (Oswestry Disability Index [ODI]), quality of life (EQ‑5D), and anterior vertebral body height (AVB). Adverse events, including adjacent vertebral fracture (AVF) and bone cement leakage (BCL), were also assessed.</p><p><strong>Results: </strong>Forty‑six studies (23 RCTs and 23 comparative cohort studies; n = 5,660) were included. Both TVA and PKP yielded greater VAS reductions than NSM at short‑term (≤ 6 months; MD - 1.28 and - 1.37; 95% CI - 1.62 to - 0.93 and - 1.82 to - 0.92) and long‑term (> 6 months; MD - 0.86 and - 0.69; 95% CI - 1.22 to - 0.50 and - 1.20 to - 0.19) follow‑up. TVA outperformed NSM in ODI improvement at short‑term (MD - 6.84; 95% CI - 9.84 to - 3.84) and long‑term (MD - 9.14; 95% CI - 14.64 to - 3.65); PKP surpassed NSM short‑term (MD - 5.59; 95% CI - 9.32 to - 1.86) but was inferior to TVA long‑term (MD 8.34; 95% CI 2.62 to 14.06). Surgical interventions uniformly outperformed NSM in quality‑of‑life gains. TVA and PKP achieved greater AVB restoration than NSM, whereas PVP carried a higher BCL risk compared to TVA and PKP. NSM was associated with the lowest probability of AVF (90.2%).</p><p><strong>Conclusions: </strong>Although PKP offers the greatest long‑term preservation of AVB, third‑generation TVA appears superior to PVP, PKP, and NSM in improving pain, functional disability, quality of life, and safety in OVCF patients. High‑quality randomized trials with extended follow‑up are required to confirm these findings.</p>","PeriodicalId":16629,"journal":{"name":"Journal of Orthopaedic Surgery and Research","volume":"20 1","pages":"810"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12398152/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Orthopaedic Surgery and Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13018-025-06233-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Optimal management of osteoporotic vertebral compression fractures (OVCFs) remains controversial. This network meta‑analysis (NMA) evaluated the relative efficacy and safety of third‑generation percutaneous vertebral augmentation (TVA), percutaneous kyphoplasty (PKP), percutaneous vertebroplasty (PVP), and non‑surgical management (NSM) in OVCFs.
Methods: A systematic search of PubMed, Embase, the Cochrane Library, and Web of Science was conducted from inception to February 1, 2025, to identify clinical trials comparing ≥ 2 of these interventions. Primary outcomes included pain intensity (Visual Analog Scale [VAS]), functional disability (Oswestry Disability Index [ODI]), quality of life (EQ‑5D), and anterior vertebral body height (AVB). Adverse events, including adjacent vertebral fracture (AVF) and bone cement leakage (BCL), were also assessed.
Results: Forty‑six studies (23 RCTs and 23 comparative cohort studies; n = 5,660) were included. Both TVA and PKP yielded greater VAS reductions than NSM at short‑term (≤ 6 months; MD - 1.28 and - 1.37; 95% CI - 1.62 to - 0.93 and - 1.82 to - 0.92) and long‑term (> 6 months; MD - 0.86 and - 0.69; 95% CI - 1.22 to - 0.50 and - 1.20 to - 0.19) follow‑up. TVA outperformed NSM in ODI improvement at short‑term (MD - 6.84; 95% CI - 9.84 to - 3.84) and long‑term (MD - 9.14; 95% CI - 14.64 to - 3.65); PKP surpassed NSM short‑term (MD - 5.59; 95% CI - 9.32 to - 1.86) but was inferior to TVA long‑term (MD 8.34; 95% CI 2.62 to 14.06). Surgical interventions uniformly outperformed NSM in quality‑of‑life gains. TVA and PKP achieved greater AVB restoration than NSM, whereas PVP carried a higher BCL risk compared to TVA and PKP. NSM was associated with the lowest probability of AVF (90.2%).
Conclusions: Although PKP offers the greatest long‑term preservation of AVB, third‑generation TVA appears superior to PVP, PKP, and NSM in improving pain, functional disability, quality of life, and safety in OVCF patients. High‑quality randomized trials with extended follow‑up are required to confirm these findings.
期刊介绍:
Journal of Orthopaedic Surgery and Research is an open access journal that encompasses all aspects of clinical and basic research studies related to musculoskeletal issues.
Orthopaedic research is conducted at clinical and basic science levels. With the advancement of new technologies and the increasing expectation and demand from doctors and patients, we are witnessing an enormous growth in clinical orthopaedic research, particularly in the fields of traumatology, spinal surgery, joint replacement, sports medicine, musculoskeletal tumour management, hand microsurgery, foot and ankle surgery, paediatric orthopaedic, and orthopaedic rehabilitation. The involvement of basic science ranges from molecular, cellular, structural and functional perspectives to tissue engineering, gait analysis, automation and robotic surgery. Implant and biomaterial designs are new disciplines that complement clinical applications.
JOSR encourages the publication of multidisciplinary research with collaboration amongst clinicians and scientists from different disciplines, which will be the trend in the coming decades.